Cyxone has already received permission to conduct research on its coronavirus drug in Poland and is awaiting a response from the relevant authorities of Ukraine, Slovakia and Hungary to conduct research in these countries.
According to Gordon.ua, the Swedish biotechnology company Cyxone has applied for a second phase of clinical trials of its drug for Rabeximod coronavirus in Ukraine.
The company stressed that the study of the Rabeximod drug should evaluate its effectiveness for patients with moderate COVID-19 who require oxygen treatment, but not support for mechanical ventilation. Their medicine should prevent the development of a severe form of the disease.
“This new way of acting to control overactive immune cells in the lungs offers hope that acute illness can be prevented”, – added Cyxone.